Faes Farma Valuation Multiples

Faes Farma Overview

About Faes Farma

Faes Farma SA is a pharmaceutical company that specializes in the research, production, distribution, and sale of prescription and generic drugs, over-the-counter medicines, food supplements and personal care treatments, as well as raw materials for the pharmaceutical use. The company develops new drugs for the treatment of allergy, venous insufficiency, and irritable bowel syndrome. It also provides animal nutrition products. Faes Farma exports its products to more than 60 countries and has operations in Spain, Portugal, Chile, and Mexico, among others.

Founded

1933

HQ

Employees

1.2K

Website

faes.es

Sectors

BiopharmaceuticalsHealth & BeautyBioTech

Financials (LTM)

Revenue: $735M

EBITDA: $149M

EV

$2B

Valuation Multiples

Multiples.vc

Start free trial

Faes Farma Financials

Faes Farma reported last 12-month revenue of $735M and EBITDA of $149M.

In the same LTM period, Faes Farma generated $149M in EBITDA and $94M in net income.

Faes Farma P&L

In the most recent fiscal year, Faes Farma reported revenue of $720M and EBITDA of $143M.

Faes Farma expects next 12-month revenue of XXX and NTM EBITDA of XXX

Faes Farma Stock Performance

Faes Farma has current market cap of $2B, and enterprise value of $2B.

Faes Farma's stock price is $5.66.

Faes Farma Valuation Multiples

Faes Farma trades at 2.4x EV/Revenue multiple, and 11.7x EV/EBITDA.

Faes Farma Financial Valuation Multiples

As of March 15, 2026, Faes Farma has market cap of $2B and EV of $2B.

Equity research analysts estimate Faes Farma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Faes Farma has a P/E ratio of 18.7x.

Faes Farma Margins & Growth Rates

Faes Farma's revenue in the last 12 month grew by 10%.

Faes Farma's revenue per employee in the last FY averaged $0.6M.

Faes Farma's rule of 40 is 30% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Faes Farma's rule of X is 45% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Faes Farma Public Comps

See public comps and valuation multiples for other Biopharmaceuticals and Health & Beauty comps.

Faes Farma M&A Activity

Faes Farma acquired XXX companies to date.

Last acquisition by Faes Farma was on XXXXXXXX, XXXXX. Faes Farma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Faes Farma Investment Activity

Faes Farma invested in XXX companies to date.

Faes Farma made its latest investment on XXXXXXXX, XXXXX. Faes Farma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).